tm logo
NEOFORDEX
Live/Registered
REGISTERED

on 01 Nov 2022

Last Applicant/ Owned by

63 rue de l'Est

Boulogne-Billancourt

FR

92100

Serial Number

97052171 filed on 29th Sep 2021

Registration Number

6888402 registered on 01st Nov 2022

in the Principal Register

Correspondent Address

Pina Campagna

Pina Campagna

576 BROAD HOLLOW RD.

MELVILLE, NY 11747

Filing Basis

No Filing Basis

Disclaimer

NO DATA

NEOFORDEX

Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, namely, amyloses, and purpura, namely, thrombocytopenic purpura; pills, capsules, tablets, and powders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseases, proliferative disease, and for treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia. chemical preparations for medical and pharmaceutical use for treating haematological diseases, namely, amyloses, and purpura, especially thrombocytopenic purpura

Mark Details


Serial Number

No 97052171

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 2655-69

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
01st Nov 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
01st Nov 2022REGISTERED-PRINCIPAL REGISTER
16th Aug 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16th Aug 2022PUBLISHED FOR OPPOSITION
27th Jul 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14th Jul 2022APPROVED FOR PUB - PRINCIPAL REGISTER
13th Jul 2022TEAS/EMAIL CORRESPONDENCE ENTERED
12th Jul 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
12th Jul 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
05th Jul 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED